Ocular Therapeutix, Inc. (NASDAQ: OCUL, "Ocular", the "Company"), a biopharmaceutical company committed to improving vision in the real world through ...

"I am thrilled to further strengthen and enrich Ocular's senior leadership team with the appointment of Namrata as Chief ...

The global diabetic macular edema market is on a steady growth trajectory, with an expected valuation of approximately USD 4,120.9 million in 2024. The market is poised to surpass USD 4,642.9 million ...

Opthea is a clinical-stage biotech firm developing Sozinibercept, targeting VEGF-C and VEGF-D for wet AMD, with Phase 3 ...

Regulatory Admission/IPOFormycon applies for admission to the Prime Standard of the Frankfurt Stock Exchange 04.11.2024 / 06:30 CET/CESTThe issuer is solely responsible for the content of this ...

Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...

Oppenheimer analyst Matthew Biegler lowered the firm’s price target on Regeneron (REGN) to $1,150 from $1,200 and keeps an Outperform ...

This suggests that the market had anticipated the possibility of such a development. The analyst further elaborated on the competitive landscape, pointing out that the presence of biosimilars in the ...

Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its covid antibody cocktail as ...

Eylea has become the leading franchise in wet AMD and other ophthalmology markets because of its similar efficacy and more convenient dosing regimen compared with Lucentis and Avastin. Dupixent's ...

Anti-VEGF Treatments: Medications such as aflibercept (Eylea) and ranibizumab (Lucentis) have revolutionized the management of wet AMD, significantly improving vision outcomes for patients. Ongoing ...